Items tagged with Scientific research
Computer simulations suggest moxifloxacin outperforms two other drugs when doses are missed
In a collection of historic skeletal remains at the Smithsonian, microscopic signs of a serious contagion lurk in an intriguing place in a sample of individuals from 100 years ago.
SEATTLE | Aug. 24, 2017 - IDRI (Infectious Disease Research Institute), on behalf of the Lilly TB Drug Discovery Initiative, announces it has entered into an agreement with Zhejiang Hisun Pharmaceutical Co., Ltd., a China-based leading biopharmaceutical company, to continue development of inhalable CPZEN-45, a tuberculosis (TB) drug candidate that could potentially treat the growing problem of antibiotic-resistant TB. Burdening its victims with increased health concerns and a high cost of treatment, drug-resistant TB occurs when Mycobacterium tuberculosis (Mtb), the bacterium that causes TB, becomes resistant to the drugs used to treat it, underscoring the need for the development of new drugs.
Scientists have unlocked a key element in understanding how human lungs fight tuberculosis (TB). They hope their research findings, which were published in the international peer reviewed journal Immunity, will help pave the way towards new treatment approaches for TB, particularly in an era of increasing antibiotic resistance to TB.
A recent study published in PLoS Pathogens found that Mycobacterium tuberculosis disrupts negative regulatory pathways in human macrophages, facilitating tissue destruction (1). The study also demonstrated, for the first time, the role of the mitogen-activated protein kinase-interacting protein kinase pathway in matrix metalloproteinase-1 secretion.
Tuberculosis is caused by Mycobacterium tuberculosis. In 2016, this was the most common causative pathogen for death by infectious diseases. Therefore, investigating the biology of infection and disease development is important in the quest to end tuberculosis. In this study, the authors conducted an integrative analysis of human and pathogen genome variations in tuberculosis. The study is published in Springer Nature's Journal of Human Genetics.
Immunocore and the Bill & Melinda Gates Foundation collaborate to develop immunotherapies for infectious diseases (post)
$40 million investment to accelerate development of Immunocore’s ImmTAV® and ImmTAB® therapeutics for infectious diseases, in particular tuberculosis and HIV
Page 26 of 35 · Total posts: 0←First 25 26 27 Last→